ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
flutiform pMDI to be available for treatment of children 5+ with asthma firstwordpharma
January 15, 2019This new paediatric licence provides for a regular asthma maintenance treatment option, with a dose of two puffs (actuations) 50/5 μg twice-daily, in children aged 5 years and over, when a combination of an inhaled corticosteroid (ICS) and a long-acting β
Pharma Sources Insight January 2025
